🚨BREAKING: The Most Comprehensive Ivermectin–Mebendazole Cancer Paper to Date Finds 37 Distinct Anticancer Mechanisms Across 25 Human Cancer Types We synthesized DECADES of evidence from over a HUNDRED studies, revealing one of the BROADEST repertoires of anticancer mechanisms ever documented for an off-patent drug combination: IVERMECTIN: 29 distinct anticancer mechanisms across 20 human cancer types. MEBENDAZOLE: 26 distinct anticancer mechanisms across 17 human cancer types. COMBINED: 37 distinct mechanism classes across 25 human cancer types in preclinical research. Across laboratory and animal studies, ivermectin and mebendazole have demonstrated multiple overlapping and complementary anticancer mechanisms: • Disrupt cancer-cell division • Trigger programmed cancer-cell death • Interfere with tumor energy production • Inhibit tumor blood-vessel formation • Suppress cancer-cell growth signaling • Target cancer stem-like cells • Interfere with metastatic spread • Modulate antitumor immune responses • Disrupt cancer-associated DNA repair pathways • Counter multidrug-resistance mechanisms • Enhance sensitivity to certain chemotherapies • Influence pathways involved in radiation resistance This is a REMARKABLE breadth of anticancer mechanisms for two inexpensive, off-patent drugs—spanning nearly every major hallmark of cancer biology. The landmark 44-page scientific paper was produced by our research team at the McCullough Foundation and The Wellness Company. Importantly, both compounds have decades of human use, established manufacturing infrastructure, well-characterized pharmacology, and low generic-drug costs. The data can NO LONGER be ignored. The scientific case for launching large clinical trials is stronger than ever. In the meantime, cancer patients will continue exercising their “right to try.” @DrHarveyRisch @McCulloughFund @twc_health @P_McCulloughMD @PeterGillooly @jathorpmfm @DrKellyVictory